BCL2 and acute myeloid leukemia: Venetoclax is an oral, potent, selective inhibitor of BCL-2 that has proven effective in various hematological malignancies—especially chronic lymphocytic leukemia (CLL) [35] or acute myeloid leukemia (AML) [36].